The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALKERMES PLC | COM | G01767105 | 44,470 | 1,441,967 | SH | SOLE | 1,441,967 | 0 | 0 | ||
BIOGEN INC | COM | 09062X103 | 29,205 | 103,202 | SH | SOLE | 103,202 | 0 | 0 | ||
EAGLE PHARMACEUTICALS INC | COM | 269796108 | 6,012 | 107,773 | SH | SOLE | 107,773 | 0 | 0 | ||
ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 53,218 | 936,777 | SH | SOLE | 936,777 | 0 | 0 | ||
EXELIXIS INC | COM | 30161Q104 | 21,140 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
INVACARE CORP | COM | 461203101 | 4,242 | 891,259 | SH | SOLE | 891,259 | 0 | 0 | ||
MCKESSON CORP | COM | 58155Q103 | 32,816 | 164,591 | SH | SOLE | 164,591 | 0 | 0 | ||
NEXTCURE INC | COM | 65343E108 | 208 | 30,927 | SH | SOLE | 30,927 | 0 | 0 | ||
REGENERON PHARMACEUTICALS | COM | 75886F107 | 44,265 | 73,143 | SH | SOLE | 73,143 | 0 | 0 | ||
SURGALIGN HOLDINGS INC | COM | 86882C105 | 6,903 | 6,332,945 | SH | SOLE | 6,332,945 | 0 | 0 | ||
TARO PHARMACEUTICAL INDUS | COM | M8737E108 | 34,715 | 545,583 | SH | SOLE | 545,583 | 0 | 0 | ||
TRAVERE THERAPEUTICS INC | COM | 89422G107 | 3,327 | 137,203 | SH | SOLE | 137,203 | 0 | 0 | ||
UNITED THERAPEUTICS CORP | COM | 91307C102 | 38,261 | 207,287 | SH | SOLE | 207,287 | 0 | 0 |